SPY772.04+0.09%QQQ745.40+0.12%BTC/USD83,994.10−0.12%DIA517.72+0.04%GLD393.05−0.09%TLT79.38+0.08%
Benzinga

AgomAb Therapeutics NV (AGMB) Stock Price, Quote, News & History

AGMBNASDAQ
Trade with Public
Trade with Public
$10.51
-0.07-0.66%
At close: Sep 25, 5:00 PM EST
$11.71
1.2011.42%
After Hours: Sep 22, 5:43 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareStock Report

AgomAb Therapeutics (AGMB) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$10.65
Close
$10.51
Volume / Avg.
164.03K / 124.99K
Day Range
$10.41 - $11.23
52 Wk Range
8.75 - 17.82
Market Cap
$576.69M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
33
Short Interest
2.13%
Days to Cover
4.6

Recent Agomab Therapeutics NV News

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Avi Kapoor

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Avi Kapoor

Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability ---- Study initiation on track, with

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI
Avi Kapoor

This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what analysts say about buying CRDO stock.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-56.73M
Investing Cash Flow (TTM)
-30.00M
Financing Cash Flow (TTM)
164.90M
Free Cash Flow (TTM)
-56.73M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
78.16M

Analyst Trends and Forecast

1
Jun
1
Jul
2
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$227.85M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
1.70
Earnings Yield % (TTM)
-14.74%
Earnings Yield % (FWD)
-19.82%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$6.17

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$339.00K
Total Cash
$221.59M
Debt to Equity
0.00
Issuance of Debt (TTM)
-$339.00K
Repayment of Debt (TTM)
-$339.00K

Key Statistics

Open
$10.65
Close
$10.51
Volume / Avg.
164.03K / 124.99K
Day Range
$10.41 - $11.23
52 Wk Range
8.75 - 17.82
Market Cap
$576.69M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
33
Short Interest
2.13%
Days to Cover
4.6

About

Sector
Health Care
Industry
Pharmaceuticals
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need....
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

Q

How do I buy AgomAb Therapeutics (AGMB) stock?

A

You can purchase shares of AgomAb Therapeutics (NASDAQ:AGMB) through any online brokerage.

View our list of the best stock brokerages

Q

Who are AgomAb Therapeutics (AGMB) competitors?

Q

What is the forecast, or price target, for AgomAb Therapeutics (AGMB) stock?

A

AgomAb Therapeutics has a consensus price target of $37.50.

Q

What is the current price for AgomAb Therapeutics (AGMB)?

A

The stock price for AgomAb Therapeutics (NASDAQ: AGMB) is $11.71 last updated September 22, 2026 at 5:43 PM EDT.

Q

Does AgomAb Therapeutics (AGMB) pay a dividend?

A

There are no upcoming dividends for AgomAb Therapeutics.

Q

When is AgomAb Therapeutics (NASDAQ:AGMB) reporting earnings?

A

AgomAb Therapeutics does not have any upcoming earnings scheduled.

Q

Is AgomAb Therapeutics (AGMB) going to split?

A

There is no upcoming split for AgomAb Therapeutics.

Q

What sector and industry does AgomAb Therapeutics (AGMB) operate in?

A

AgomAb Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved